ProKidney Corp Ordinary Shares - Class A PROK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.31–1.47
- 52-Week Range
- $1.30–3.48
- Bid/Ask
- $1.31 / $1.32
- Shares Outstanding
- 208.93M
- Market Cap
- $277.87M
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 245.84
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 231
- Website
- https://www.prokidney.com
Valuation
|
Metric
|
PROK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 245.84 |
Price/Cash Flow | — |
Price/Earnings
PROK
Financial Strength
|
Metric
|
PROK
|
|---|---|
Quick Ratio | 8.04 |
Current Ratio | 8.36 |
Interest Coverage | −9,327.16 |
Quick Ratio
PROK
Profitability
|
Metric
|
PROK
|
|---|---|
Return on Assets (Normalized) | −45.01% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −52.75% |
Return on Assets
PROK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|J#l<>Tc | LOCK|@J%GJ | $127B | |||
| Moderna Inc
MRNA
| LOCK|W@Q<W@ | LOCK|C! | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W&>N??t | LOCK|#nDt | $81B | |||
| argenx SE ADR
ARGX
| LOCK|n!!R&S! | LOCK|KfT | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|L!v>C^ | LOCK|$#K | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Dx^PD< | LOCK|ktk> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>%LxWhT | LOCK|lFtH | $27B | |||
| Incyte Corp
INCY
| LOCK|Yx>bx># | LOCK|pH# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|YL%!kqm | LOCK|vb | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j#tR#qX | LOCK|#R | $14B |
United States